Liquidambaric acid inhibits cholangiocarcinoma progression by disrupting the STAMBPL1/NRF2 positive feedback loop
This study firstly reveals that STAMBPL1 promotes cholangiocarcinoma progression by upregulating NRF2, indicating that targeting the STAMBPL1/NRF2 axis is a novel therapeutic strategy. Additionally, our findings firstly suggest that LDA can bind to STAMBPL1, inhibiting NRF2 deubiquitination and offering significant therapeutic potential.
Authors
- Zhihuai Wang (ORCID: https://orcid.org/0000-0001-7156-3132)
- Chunfu Zhu
- Yuhang Shen (ORCID: https://orcid.org/0009-0001-8917-7712)
- Xihu Qin
- Yuan Gao (ORCID: https://orcid.org/0000-0001-6635-9911)
- Yinjie Zhang
Institutions
- Changzhou No.2 People's Hospital (CN)
Publication Details
- Journal
- Phytomedicine
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1016/j.phymed.2024.156303
- Citations
- 8
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.58